FDMT.US 4D Molecular Therapeutics Inc

Healthcare Biotechnology USA Stocks
12.23 USD
Close of Nov 14, 2026
6.96 16.93
Market cap
USD 676M
P/E
-
P/B
1.64x
ROE
-86.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FDMT.US undervalued?

Graham number

The Graham number of 4D Molecular Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

4D Molecular Therapeutics Inc fundamental analysis

No fundamental analysis for 4D Molecular Therapeutics Inc yet.

4D Molecular Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating…

Full company profile